A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Phase 2TerminatedNCT00347646

Bausch & Lomb Incorporated4 enrolled

Overview

Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Vitreoretinal Traction Syndrome

Interventions

PlasminDRUG

27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are in need of a vitrectomy. Exclusion Criteria: * A PVD in the study eye as assessed by the investigator using ophthalmic and alternative examination techniques. * A history of vitrectomy in the study eye. * A media opacity that precludes quality examination of the vitreous and fundus in the study eye.

Locations (1)

University Hospitals of Cleveland

Cleveland, Ohio, United States

Outcomes

Primary Outcomes

Presence of a Posterior Vitreous Detachment (PVD)

Presence of posterior vitreous detachment evaluated durning virectomy

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.